MicroPort Scientific Corporation (MSK) - Net Assets
Based on the latest financial reports, MicroPort Scientific Corporation (MSK) has net assets worth €1.50 Billion EUR (≈ $1.75 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.70 Billion ≈ $4.32 Billion USD) and total liabilities (€2.20 Billion ≈ $2.57 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of MicroPort Scientific Corporation to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.50 Billion |
| % of Total Assets | 40.58% |
| Annual Growth Rate | 11.87% |
| 5-Year Change | -32.35% |
| 10-Year Change | 332.98% |
| Growth Volatility | 37.43 |
MicroPort Scientific Corporation - Net Assets Trend (2013–2025)
This chart illustrates how MicroPort Scientific Corporation's net assets have evolved over time, based on quarterly financial data. See MSK days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for MicroPort Scientific Corporation (2013–2025)
The table below shows the annual net assets of MicroPort Scientific Corporation from 2013 to 2025. For live valuation and market cap data, see MicroPort Scientific Corporation stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.50 Billion ≈ $1.75 Billion |
+31.04% |
| 2024-12-31 | €1.14 Billion ≈ $1.34 Billion |
-18.40% |
| 2023-12-31 | €1.40 Billion ≈ $1.64 Billion |
-21.74% |
| 2022-12-31 | €1.79 Billion ≈ $2.10 Billion |
-19.16% |
| 2021-12-31 | €2.22 Billion ≈ $2.59 Billion |
+59.77% |
| 2020-12-31 | €1.39 Billion ≈ $1.62 Billion |
+112.24% |
| 2019-12-31 | €653.97 Million ≈ $764.55 Million |
+23.64% |
| 2018-12-31 | €528.95 Million ≈ $618.39 Million |
+20.36% |
| 2017-12-31 | €439.45 Million ≈ $513.77 Million |
+26.83% |
| 2016-12-31 | €346.48 Million ≈ $405.07 Million |
+9.01% |
| 2015-12-31 | €317.83 Million ≈ $371.57 Million |
-7.54% |
| 2014-12-31 | €343.74 Million ≈ $401.87 Million |
-11.96% |
| 2013-12-31 | €390.43 Million ≈ $456.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MicroPort Scientific Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1407.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.53 Billion | 257.74% |
| Total Equity | €980.82 Million | 100.00% |
MicroPort Scientific Corporation Competitors by Market Cap
The table below lists competitors of MicroPort Scientific Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
$1.55 Billion |
|
Shipping Corporation Of India Limited
NSE:SCI
|
$1.55 Billion |
|
Jinzhou Jixiang Molybdenum Co Ltd
SHG:603399
|
$1.55 Billion |
|
Realia
MC:RLIA
|
$1.55 Billion |
|
Galapagos N.V.
AS:GLPG
|
$1.55 Billion |
|
China Railway Construction Corporation Limited
F:4FF
|
$1.55 Billion |
|
Taiji Computer Corp Ltd
SHE:002368
|
$1.55 Billion |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MicroPort Scientific Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 603,473,000 to 980,815,000, a change of 377,342,000 (62.5%).
- Net income of 48,519,000 contributed positively to equity growth.
- Other factors increased equity by 337,058,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €48.52 Million | +4.95% |
| Other Changes | €337.06 Million | +34.37% |
| Total Change | €- | 62.53% |
Book Value vs Market Value Analysis
This analysis compares MicroPort Scientific Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.52x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.28 | €0.70 | x |
| 2018-12-31 | €0.28 | €0.70 | x |
| 2019-12-31 | €0.32 | €0.70 | x |
| 2020-12-31 | €0.62 | €0.70 | x |
| 2021-12-31 | €0.82 | €0.70 | x |
| 2022-12-31 | €0.62 | €0.70 | x |
| 2023-12-31 | €0.41 | €0.70 | x |
| 2024-12-31 | €0.33 | €0.70 | x |
| 2025-12-31 | €0.51 | €0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MicroPort Scientific Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.88%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 3.77x
- Recent ROE (4.95%) is above the historical average (-12.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 6.15% | 15.82% | 0.29x | 1.33x | €-15.05 Million |
| 2014 | -17.37% | -16.74% | 0.38x | 2.75x | €-93.69 Million |
| 2015 | -3.87% | -3.22% | 0.51x | 2.35x | €-43.34 Million |
| 2016 | 4.25% | 3.63% | 0.50x | 2.33x | €-19.15 Million |
| 2017 | 4.69% | 4.24% | 0.49x | 2.25x | €-21.34 Million |
| 2018 | 5.40% | 3.57% | 0.53x | 2.88x | €-20.37 Million |
| 2019 | 8.92% | 5.83% | 0.50x | 3.08x | €-5.62 Million |
| 2020 | -16.96% | -29.48% | 0.26x | 2.19x | €-304.05 Million |
| 2021 | -18.55% | -35.51% | 0.18x | 2.94x | €-425.56 Million |
| 2022 | -38.46% | -51.91% | 0.21x | 3.52x | €-550.02 Million |
| 2023 | -63.03% | -50.24% | 0.24x | 5.19x | €-553.41 Million |
| 2024 | -35.47% | -23.16% | 0.25x | 6.02x | €-274.39 Million |
| 2025 | 4.95% | 4.88% | 0.27x | 3.77x | €-49.56 Million |
Industry Comparison
This section compares MicroPort Scientific Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $42,158,844,269
- Average return on equity (ROE) among peers: -65.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MicroPort Scientific Corporation (MSK) | €1.50 Billion | 6.15% | 1.46x | $1.55 Billion |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $144.88K |
| BIORETEC OY (0TN) | $4.34 Million | -138.72% | 0.98x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $388.36 Billion | 11.79% | 0.37x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $683.20 Million | 13.73% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $931.03K | -443.77% | 0.60x | $28.30 Million |
| Medtronic PLC (2M6) | $9.38 Billion | 27.14% | 1.10x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $3.02 Billion | -19.02% | 0.05x | $319.35 Million |
| AVITA Medical Inc (51KB) | $115.66 Million | -22.98% | 0.09x | $172.49 Million |
| BRAINCOOL AB (5YL) | $45.23 Million | -85.67% | 1.20x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; an… Read more